Genprex, Inc. (NASDAQ:GNPX – Get Free Report) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 247,400 shares, an increase of 430.9% from the July 31st total of 46,600 shares. Approximately 9.7% of the shares of the stock are short sold. Based on an average daily volume of 231,900 shares, the days-to-cover ratio is presently 1.1 days.
Institutional Trading of Genprex
An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC lifted its position in shares of Genprex, Inc. (NASDAQ:GNPX – Free Report) by 122.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 14.05% of the company’s stock.
Genprex Trading Down 1.0 %
Genprex stock opened at $0.70 on Thursday. Genprex has a 12-month low of $0.56 and a 12-month high of $22.41. The business’s 50-day moving average price is $1.56 and its two-hundred day moving average price is $2.53.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Genprex in a research report on Wednesday, May 15th.
Get Our Latest Research Report on Genprex
Genprex Company Profile
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
See Also
- Five stocks we like better than Genprex
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Stocks to Watch as the Dollar Declines to a 7-Month Low
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MGM Insiders Bet Big on Its Undervalued Stock
- 3 Monster Growth Stocks to Buy Now
- BHP Stock: The Under-the-Radar Growth Story in Commodities
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.